Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Reports Increased Fiscal Q4 Losses on Higher Expenses


Arrowhead Research this week reported its fiscal fourth-quarter financial results, posting a higher net loss amid increased operating expenses.

The company also said that efforts to integrate its subsidiaries into a single company are underway.

According to Arrowhead, its net loss for the three-month period ended Sept. 30 was $2.8 million, or $0.39 a share, versus a loss of $2 million, or $0.28 per share, in the same period a year before.

Arrowhead recorded revenues of $296,000 in the quarter, versus no revenues a year earlier. However, the company's fourth-quarter operating costs jumped to $2.9 million from $1.8 million last year.

In a statement, Arrowhead President and CEO Christopher Anzalone said that the company is “well underway [toward] integrating our subsidiaries and programs into one cohesive operating company with multiple products and technologies.”

Arrowhead has maintained a strong interest in RNAi through its Calando Pharmaceuticals subsidiary, and it recently acquired the US RNA therapeutic assets of Roche (GSN 10/27/2011). The company also holds a stake in nanomedicines firm Leonardo Biosystems, which has developed a delivery technology with potential in RNAi (GSN 5/20/2010).

The Scan

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.